Gyg Share Discussion Threads

[orvis] 21/10/2003 14:18

Looks like buyers are nibbling again. Well oversold in my view. Worth re-reading the interims - 2nd half to be stronger than first.

[gopher] 21/10/2003 13:52

The decline has become uncomfortable for holders, is there bad news to come or is this a buying opportunity; the Nomura analysis was the most interesting ( post 31). In the context of reecent Nasdaq biotech and dollar falls the decline is understandable but UK Healthcare/biotech has been positive recently.

[vixen] 20/10/2003 11:32

Is this sell coming to a climax?

[pacman88] 15/10/2003 11:53

Framlington selling down. Have sold 500,000 shares since last notification. May explain why this has moved down post results. Once overhang clears I expect this to retrace.

RNS Number:9180Q
Gyrus Group PLC
15 October 2003

Gyrus Group plc (the "Company")

Notification of Major Interests in Shares

The Company received a notification on 14 October 2003 from Framlington
Investment Management Limited, informing it that as investment managers they
have an interest in 7,947,369 Shares, representing 9.54% of the Company's issued
Ordinary Share Capital. The shares are registered in the name of HSBC Global
Custody Nominee (UK) Limited and State Street Nominees Limited.

15 October 2003

[vixen] 13/10/2003 08:46

Does this increase Royal London's percentage?

heavy numbers changing hands at the mid today and Friday, look's to be buyers should underpin the price here.

[ok,yah] 10/10/2003 11:19

Gyrus Group plc (the "Company")

Notification of Major Interests in Shares

The Company received a notification today, from Royal London Unit Trust Managers
Limited, informing them that they have a notifiable interest in 4,135,507
Shares, representing 4.96% of the Company's issued Ordinary Share Capital

[ok,yah] 03/10/2003 15:03

Lots of broker support after results - Looks ready for a bounce to me after the profit taking

[pacman88] 02/10/2003 12:30

Gyrus Group plc (GYG) Country: GBR
Currency: GBP


Select View:
ConsensusDetailed

Select Item:
SalesEBITDAEBITPre-Tax ProfitEPSCFPSDPSREC Select Period:
Fiscal Annual




End Of Day: 30-Sep-2003

Recommendation Most Recent
Rec Confirm Date Recommendation
Mean
Median
# Estimates
High
Low
Rec Distrib/Std Dev
OUTPERFORM (1.89)
OUTPERFORM (1.89)
9


4/2/3/0/0/0

Baird
08-Sep-03 HOLD
Estimate Date 16-Jun-03

Confirm Date
Prev Estimate
Prev Est Date
08-Sep-03
HOLD
16-Jun-03

Dresdner Kleinwort Wasserstein
30-Sep-03 BUY
Estimate Date 28-May-03
Beth Baird

Confirm Date
Prev Estimate
Prev Est Date
30-Sep-03
BUY
28-May-03

Dryden Wealth Management Limited
10-Sep-03 HOLD
Estimate Date 10-Sep-03

Confirm Date
Prev Estimate
Prev Est Date
10-Sep-03
--
--

Evolution Beeson Gregory
09-Sep-03 OUTPERFORM
Estimate Date 27-Aug-03

Confirm Date
Prev Estimate
Prev Est Date
09-Sep-03
--
26-Aug-03

Investec Securities (UK)
11-Sep-03 HOLD
Estimate Date 11-Sep-03

Confirm Date
Prev Estimate
Prev Est Date
11-Sep-03
--
--

Nomura International PLC
05-Aug-03 OUTPERFORM
Estimate Date 11-Jul-03

Confirm Date
Prev Estimate
Prev Est Date
05-Aug-03
--
--

Numis Securities
11-Jul-03 BUY
Estimate Date 11-Jul-03

Confirm Date
Prev Estimate
Prev Est Date
11-Jul-03
BUY
21-Apr-03

Panmure
10-Sep-03 BUY
Estimate Date 10-Sep-03

Confirm Date
Prev Estimate
Prev Est Date
10-Sep-03
BUY
09-Jul-03

Rowan Dartington
29-Aug-03 BUY
Estimate Date 15-Apr-03

[diogenesj] 13/9/2003 13:33

Perhaps more important, although the results were slightly disappointing and it appears that forecasts have been shaved slightly, the shares still look good value.

They are recommended as a buy in this week's Investor's Chronicle, but we shouldn't be put off by that (the derided organ is not always wrong).

[vixen] 13/9/2003 08:09

Don't take it for granted the big ones are all sells. The T trade in particular could well be a buy. Either way it survvived and should now pull some of last weeks losses back. As the T10 trades close.

[polythene] 13/9/2003 00:36

Slightly worrying that there are loads of retail buys with two large 50k + 25K sells? and the price has barely moved. Are there a few more to be shifted at this price before we get a rise or are we in danger of falling further?

DTMT

[diogenesj] 12/9/2003 22:01

I'm here, Polythene, but I can't answer your question. :-)

[polythene] 12/9/2003 15:55

Hallo? Is there anyone there?

[diogenesj] 09/9/2003 15:47

Useful comments. Thanks, Pacman.

[pacman88] 09/9/2003 11:20

Gyrus confident of further growth after strong H1.

715 words
9 September 2003
AFX UK Focus
English
Copyright AFX News, 2003 All reproduction and presentation rights reserved.

LONDON (AFX) - Gyrus Group PLC, which supplies medical devices to reduce trauma and complications in surgery, said it is confident of further strong growth after it reported a rise in revenues, increased operating profits and strong cash generation for the first half to June 30 2003.

The group also announced some senior board changes today and the acquisition of Benelux medical product distributor Entermed NV for up to 2.1 mln eur.

On the future, Gyrus was positive and said it is maintaining its revenue growth target in the high teens for 2004.

Gyrus' group revenues from continuing activities for the first half were 37.2 mln stg, up 6 pct, on a constant exchange rate (CER) basis. Revenues from direct sales activities were up 14 pct on a CER basis.

Gross margins remain strong at 60.3 pct.

Profit before tax and amortisation grew 22 pct to 3.0 mln stg from 2.5 mln.

Cash generation from operating activities was 5.1 mln stg in the period.

Executive chairman Brian Steer said Gyrus benefited in particular from the investments made in building up the direct sales infrastructure.

"Looking forward, the board continues to put in place the elements necessary for sustained growth and profitability," said Steer.

He said Gyrus' technology and new product platform are state-of-the-art. The quality and cost of its products are controlled through its own manufacturing operations and the group will continue to focus its resources on building up its sales and distribution capabilities on a global basis.

"With a strengthened management team now in place, the board remains confident of further strong growth."

As part of the management changes, founders Colin and Mark Goble will, over the coming months, move into advisory roles within a series of management changes which strengthens the operations board.

On Oct 1, Roy Davis will relinquish his non-executive role to become chief operating officer, Simon Shaw will join the group as chief financial officer in place of Tom Murphy who is returning to the US to take up his new appointment as president of Gyrus Medical Inc. Chris Smith, currently president of Gyrus Medical Inc, will take on global responsibility for the business divisions as president of Gyrus Group.

The board believes that these changes will ensure the continued development of the business in achieving its goal of sustainable growth and optimal profitability in future years.

In the period under review the group said the translation effects of a weakened dollar impacted financial results as compared to the same period in 2002. Without the currency impact, revenue growth would have been 6 pct on a constant dollar basis for the ongoing business.

Prior year revenues also included 1.1 mln stg of revenues from the drapes business divested in November 2002, the company pointed out.

The group also said it expects that the cash and available borrowings will be sufficient to meet its current goals and positive cash generation to continue throughout 2003. Net debt was 15.9 mln stg at June 30 2003 compared to 17.9 mln at Dec 31 2002.

The group's investment in R&D for the first half was 3.2 mln stg compared to 4.4 mln in the same period of 2002. The group said it has seen the level of investment fall as its focus has shifted from the costly development of platforms towards the product and procedural development initiatives that can impact revenues now that there is a larger installed base of generators.

Throughout the remainder of the year, R&D activities will focus on incremental expansions to the new product lines and the development of key products in General and Head and Neck surgery for introduction in 2004.

Longer-term initiatives with collaborative partners in the field of surgical biomaterials will continue.

Gyrus said the purchase of Entermed BV, which currently distributes Gyrus' range of ENT products and a broader product portfolio to surgeons in Benelux, provides the group with a platform to grow its revenues in Benelux and reflects the group's strategy of expanding its direct selling model.

Entermed had revenues of some 5.2 mln eur in the last twelve months.

[e-mail]

slm/.

[pacman88] 09/9/2003 10:25

Good results and nice pullback. Bought a few and will add as results get digested.

[orvis] 08/9/2003 18:33

Masses of buying resumed today - mostly small retail purchases (look like top ups ahead of the results to me)

[orvis] 08/9/2003 18:25

Results tomorrow according to my Sunday paper.

[chambeaj] 08/9/2003 10:57

Hope I haven't bought into a turkey with this one!!
Have to say I am a bit dissappointed with the share price
movement over the last week given that excellant trading statement.

[orvis] 05/9/2003 13:59

Hmm a hanful of sells and she's marked down.
This encourages some more sells and back we are where we started.
Those MM's - they can always make money!

[orvis] 04/9/2003 22:44

Totally buys today, including 2 MM buys!
Today's rise still does not come near reflecting the solid buying in the last 5 days and the institutional interest.
Share price still being held back I think. All MMs must run out of stock soon and then rises could be significant.